May 13, 2019
Eisai said on May 10 that it has inked a license pact with German drug maker Medac, grabbing exclusive commercialization rights for the Hamburg-based firm’s rheumatoid arthritis (RA) agent methotrexate (MTX) subcutaneous injection in Japan. Under the deal, the SC...read more